Please access the RSClin® Tool through your Exact Sciences Portal. Copyright © 2004-2025 Exact Sciences Corporation All rights reserved. Oncotype DX Tools Few studies have compared the performance of gene-expression profiling tests (e.g. Oncotype-Dx) to clinico-pathologic risk calculators (e.g. Prognostic Tool RSClin Introduced for Early Breast Cancer - The
The RSClin tool provides an estimate of risk of distant metastasis at 10 years with hormonal therapy alone, as well as an estimate of Validation of the RSClin risk calculator in the National Cancer Data The RSClin prognostic tool integrates OncotypeDx and clinicopathologic features to predict distant recurrence and chemotherapy benefit.
Validation of the RSClin risk calculator using the National Cancer A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score® result provides
RSClin® Tool N+: more accurate estimates of recurrence risk OP, your oncologist should how you the calculation. It's a calculator on a site that requires instititutional access. 0.
RSClinN+ is a companion to RSClin, which was released in 2021. RSClin provides similar estimates for people with early-stage hormone Does RSClin provide additional information over classic clinico
Tool Gives More Precise Recurrence Risk, Chemo Benefit Estimate 549Background: Clinical practice guidelines recommend the use of genomic assays to aid decision making regarding the use of adjuvant
RSClin® Tool RSClin oncotype scores — Community Discussion Forums MD Anderson faculty members have created several clinical calculators, also known as nomograms, to predict treatment outcomes, survival and response.
Clinical Calculators | MD Anderson Cancer Center RSClin, which aims to individualize the estimate of recurrence A patient-specific estimator of absolute chemotherapy benefit was